What is ADPKD?

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a hereditary & progressive disease characterized by gradual enlargement of cysts in both kidneys leading to renal insufficiency, or reduction in kidney function, ultimately leading to End-Stage Renal Disease (ESRD).


  • The JINARC® RMP (Risk Management Program) is designed to manage the risk of serious and potentially fatal liver injury associated with using JINARC®, and the RMP ensures that the benefits of using JINARC® outweigh its risks.
  • There have been reports of acute liver failure requiring liver transplantation in patients with ADPKD on the post-marketing ADPKD experience. Discontinuation in response to laboratory abnormalities or sign or symptoms* of liver injury can reduce the risk of severe hepatotoxicity.
  • *These symptoms may include: fatigue, nausea, abdominal discomfort, fever, rash, yellowing of the skin or eyes, dark urine, or itching.


To prescribe JINARC®, healthcare providers need to follow these steps:

  1. Complete a one-time certification process by passing the Jinarc® Risk Management Assessment.
  2. Counsel patients and conduct baseline liver testing before enrolling them in the RMP, then write the prescription.
  3. Continuously monitor patients, conduct liver function testing at 2 weeks and 4 weeks after treatment initiation, monthly for 2-18 months, and every 3 months thereafter.


To receive JINARC®, patients need to follow these steps:

  1. Consult your healthcare provider to know if you are eligible for Jinarc® treatment.
  2. Complete liver function test (LFT) before treatment initiation. Your healthcare provider will give your Jinarc prescription once done with the review of your LFT results.
  3. Enroll in the RMP by calling JINARC® Patient Support Team.
  4. Complete liver function testing on the 2nd and 4th week of the 1st month of treatment, monthly for 2-18 months, and every 3 months thereafter.